ReviewExpert opinion on drug metabolism & toxicology2009
Modeling HCV kinetics under therapy using PK and PD information.
Review in Expert opinion on drug metabolism & toxicology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection.Antiviral therapy · 2016Trial
- A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV.Antiviral therapy · 2015Trial
- Trial
- Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.Hepatology (Baltimore, Md.) · 2012Trial
- Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy.AIDS (London, England) · 2011Trial
- How robust are estimates of key parameters in standard viral dynamic models?PLoS computational biology · 2024Article
- How to mathematically optimize drug regimens using optimal control.Journal of pharmacokinetics and pharmacodynamics · 2018Article
- Population pharmacokinetics of peginterferon α2a in patients with chronic hepatitis B.Scientific reports · 2017Article
- Modelling hepatitis C therapy--predicting effects of treatment.Nature reviews. Gastroenterology & hepatology · 2015Review
- HCV Kinetic Models and Their Implications in Drug Development.CPT: pharmacometrics & systems pharmacology · 2015Review
- Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy.Antiviral therapy · 2015Article
- Viral kinetic modeling: state of the art.Journal of pharmacokinetics and pharmacodynamics · 2014Review
- A hepatitis C virus infection model with time-varying drug effectiveness: solution and analysis.PLoS computational biology · 2014Article
- Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methods.CPT: pharmacometrics & systems pharmacology · 2014Article
- Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection.Antimicrobial agents and chemotherapy · 2013Article
- Hepatitis C viral kinetics: the past, present, and future.Clinics in liver disease · 2013Review
- Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?Antiviral therapy · 2012Review
- Targeting HCV entry for development of therapeutics.Viruses · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundMathematical models have proven helpful in analyzing the virological response to antiviral therapy in hepatitis C virus (HCV) infected subjects.
objectiveTo summarize the uses and limitations of different models for analyzing HCV kinetic data under pegylated IFN therapy.
methodsWe formulate mathematical models and fit them by nonlinear least square regression to patient data to estimate model parameters. We compare the goodness of fit and parameter values estimated by different models statistically. RESULTS/
conclusionThe best model for parameter estimation depends on the availability and the quality of data as well as the therapy used. We also discuss the mathematical models that will be needed to analyze HCV kinetic data from clinical trials with new antiviral drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.